FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 24 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March New on NCI’s Websites for March 2025 MOST POPULAR For Some Women with Breast Cancer, Cost Influences Decisions about Surgery September 6, 2019 A tribute to Professor Anne Charlton June 23, 2020 Trastuzumab Deruxtecan Demonstrates Efficacy in HER2-positive and HER2-low Advanced Gastric Cancer July 6, 2021 Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment September 24, 2021 Load more HOT NEWS Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to... Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than Expected Lo que deben saber las personas con cáncer de mama y... The Recently Leaked Secret to Marijuana News Discovered
